Greenberg Traurig Represents ARKO Petroleum Corp. in $200M Initial Public Offering [Accessibility Statement] Skip NavigationMIAMI, Feb. 23, 2026 /PRNewswire/ -- Global law firm [Greenberg Traurig, LLP] represented wholesale fuel distributor ARKO Petroleum Corp. (Nasdaq: APC), a subsidiary of ARKO Corp. (Nasdaq: ARKO), in connection with its $200 million initial public offering (IPO). The offering closed Feb. 13 and provided the company with net proceeds of approximately $183.2 million.The IPO consisted of 1 ...

Unisys Strengthens Device Subscription Service To Support Complex Edge Computing and IoT Deployments [Accessibility Statement] Skip NavigationCollaboration with Dell Technologies empowers organizations with smarter, more agile digital workplace solutionsBLUE BELL, Pa., Feb. 23, 2026 /PRNewswire/ -- [Unisys] (NYSE: UIS) is advancing its [Device Subscription Service](DSS), in collaboration with [Dell Technologies]. This strengthened alliance of more than 30 years delivers comprehensive and flexible solutions ...

Core Insights - The Gallagher AI Adoption and Risk Survey indicates that 82% of businesses report positive impacts from AI integration, with 63% having fully operationalized AI in their operations, a significant increase from 45% in 2025 [1][1][1] - A majority of respondents (83%) believe AI will drive future revenue growth, while 93% feel confident in their understanding of AI risks [1][1][1] AI Adoption and Implementation - 63% of businesses have fully implemented AI, focusing on IT operations, client-facing functions, and analytics, up from 45% in the previous year [1][1][1] - Nearly two-thirds (63%) of organizations are measuring ROI from AI, estimating an average of 28 months to realize returns [1][1][1] Challenges and Concerns - Key challenges include AI errors, misinformation, and hallucinations (57%), legal and reputational risks from AI misuse (56%), and data protection and privacy violations (55%) [1][1][1] - Over half of respondents report skills gaps and recruitment challenges related to AI [1][1][1] Ethical Considerations and Human Element - 46% of organizations have appointed an AI ethics officer to address ethical considerations in AI deployment [1][1][1] - The importance of maintaining a human element in AI technology, including personal accountability, governance, and training, is emphasized [1][1][1] Customer Experience Focus - The survey highlights the need to prioritize customer experience in AI adoption, as stated by Gallagher's Global Chief Digital Officer [1][1][1] - Gallagher's ongoing investment in data, analytics, and workforce skill development aims to enhance client outcomes in a rapidly evolving landscape [1][1][1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misrepresenting information regarding its drug AMT-130 during a specific class period, leading to significant stock price decline [1]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [1]. Legal Allegations - The lawsuit claims that uniQure misrepresented the FDA approval status of its Pivotal Study for AMT-130 and downplayed the potential delay in its Biologics License Application (BLA) timeline [1]. - The complaint highlights that the FDA did not agree that the Phase I/II data could serve as primary evidence for a BLA submission, causing uncertainty regarding the submission timeline [1]. Stock Performance Impact - Following the disclosure on November 3, 2025, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share the next trading day [1].

Core Viewpoint - Viewbix Inc. is strategically acquiring Quantum X Labs to enhance its position in the quantum technology sector, targeting various applications and leveraging Israel's academic strengths in the field [1] Acquisition Details - Viewbix signed a definitive agreement to acquire 85-100% of Quantum X Labs, with completion expected within 90 days, pending due diligence and regulatory approvals [1] - The acquisition includes Quantum X Labs' expanding patent portfolio, particularly in quantum error correction [1] Financial Aspects - A private placement financing was amended in early January 2026, involving 800,000 units at approximately $1.75, raising about $1.4 million gross, with an additional potential of up to $1.68 million in warrants [1] - Majority stockholder written consent was secured on January 5, 2026, and a definitive Schedule 14C was filed with the SEC on January 15, 2026 [1] Quantum X Labs' Portfolio - Quantum X Labs is developing several key technologies: - Nuclear Quantum focuses on reactor simulation and materials science [1] - QuantumQ Security aims to protect data and infrastructure [1] - Quantum Aton Accuracy leverages quantum principles for precision applications [1] - Cliniquantum is working on drug discovery methods using quantum-enhanced techniques [1] - Quantum Transportation addresses scalability issues in quantum computing [1] - Quantum Gyro is developing technology for GPS-denied environments [1] Market Position and Ecosystem - Quantum X Labs is positioned to tap into significant near-term total addressable markets (TAMs) in navigation, precision timing, security, and nuclear simulation [1] - The company benefits from Israel's elite university ecosystem, which provides a talent edge and fosters interdisciplinary collaboration [1]

S.A. de C.V. of Hermosillo, Sonora, Mexico.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Qualified PersonsThe mineral resource was estimated by Ben Eggers, MAIG, P.Geo. of SGS Geological Services, an independent Qualified Person as defined by NI 43-101. Eggers conducted a site visit to the Columba Property on May 28, 2025. The mineral resource was peer ...

SÃO PAULO, Feb. 23, 2026 AZUL S.A. (B3: AZUL53; OTC: AZULQ) ("Azul" or "Company"), the largest airline in Brazil in number of cities served and direct domestic routes, today announced the appointment of John S. Slattery to its Strategy Committee, effective February 20, 2026. John joins Azul at a pivotal moment as the Company finalizes its emergence from its Chapter 11 process, bringing decades of global leadership experience in the aerospace and aviation industries. Azul S.A. (B3: AZUL53; OTC: AZULQ), the l ...

Core Insights - CNO Financial Group recognized associate Stacy Muentzer Oakey as Volunteer of the Year and announced donations to 12 nonprofits through its Invested in Giving Back® program [1] Group 1: Volunteer Recognition - Stacy Muentzer Oakey was honored for her dedicated service to Scouting America's Pathway to Adventure Council, receiving a $10,000 donation for the organization [1] - In 2025, Muentzer Oakey contributed over 410 hours of service, including 16 nights of camping and more than 1,500 miles of travel for Scout events [1] - The recognition reflects her significant impact on Troop 216 and sets a standard for volunteer service within the organization [1] Group 2: Invested in Giving Back Program - CNO's Invested in Giving Back program, now in its eighth year, allows associates to nominate and vote for community programs to receive charitable donations [1] - This year, CNO will donate a total of $180,000 across 12 nonprofit organizations [1] - The program exemplifies CNO's commitment to community support and empowers associates to influence corporate philanthropy [1] Group 3: Company Overview - CNO Financial Group, Inc. provides life and health insurance, annuities, and financial services, securing the future of middle-income America [1] - The company manages 3.2 million policies and has total assets of $38.8 billion [1] - CNO employs 3,300 associates and collaborates with 5,000 exclusive agents and over 7,000 independent partner agents [1]

launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports ...

Core Points - The Corcept Therapeutics class action lawsuit seeks to represent investors who purchased common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1] - The lawsuit claims that Corcept misrepresented the support for its relacorilant New Drug Application (NDA), suggesting it was close to FDA approval despite known concerns from the FDA regarding clinical evidence [1] - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the relacorilant NDA, leading to a more than 50% drop in the company's stock price [1] - The FDA's CRL indicated that the clinical studies submitted were insufficient to demonstrate relacorilant's efficacy, and the FDA had previously warned Corcept about significant review issues [1] Company Overview - Corcept Therapeutics is engaged in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a lead candidate for treating hypercortisolism [1] - The company has faced significant scrutiny regarding the adequacy of its clinical development program for relacorilant, which has implications for its future product approvals and market performance [1] Legal Context - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]